Affordable Access

Access to the full text

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

Authors
Type
Published Article
Journal
Investigational New Drugs
Publisher
Springer-Verlag
Publication Date
Jun 09, 2013
Volume
31
Issue
4
Pages
1094–1094
Identifiers
DOI: 10.1007/s10637-013-9984-1
Source
LBMCC
Keywords
License
Green

Abstract

Cardiac glycosides have a long history in the treatment of cardiac disease. However, several preclinical studies as well as two phase I studies have shown that cardenolides may also possess anticancer effects. The mechanisms of these anticancer effects may include intracellular decrease of K(+) and increase of Na(+) and Ca(2+); intracellular acidification; inhibition of IL-8 production and of the TNF-α/NF-κB pathway; inhibition of DNA topoisomerase II and activation of the Src kinase pathway. To date three cardiac glycosides have been developed for treatment of cancer and were tested in a phase 1 clinical trial to determine dose limiting toxicities and maximum tolerated dose. Future studies of this novel class of anticancer drugs are warranted to determine their possible role in cancer treatment.

Report this publication

Statistics

Seen 235 times